Loading...

BRNS

BWY

BRAINSWAY LTD

(BWAY)

2025 6-K

Policy Announcement

Deep TMS Expansion

Clinical Trial Launch

FDA Clearance Received

Financial Results Report

NIH Grant Award

Warrant Exercise

Q2 Earnings Report

Shareholder Meeting Results

Filing Announcement

Filing Notification

Positive Pilot Data

Feasibility Data Reported

Shareholder Meeting Results

Expansion in Asia

Private Placement Announcement

Expansion Announcement

PTSD Reimbursement Approved

New CMO Appointment

Brainsway Filing

Shareholder Meeting Results

Distribution Agreement

Clinical Trial Announcement

FDA Label Expansion

First Quarter Results

TMS Expansion Update

Parkinson's Treatment Review

Partnership Expansion

Financial Results Report

Clinical Evaluation Start

External Links:

Brainsway Ltd. announced receiving FDA clearance for its Deep TMS™ as an adjunct therapy for major depressive disorder (MDD) in adolescents aged 15 to 21 on November 13, 2025. This event is significant as it indicates a positive development in their product offerings.

AI Assistant

BRAINSWAY LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.